This invention describes an innovative cancer drug specifically targeting SH-SY5Y neuroblastoma cells through caffeic acid phenethyl ester (CAPE)-loaded microvesicles. Microvesicles derived from differentiated skin stem cells are loaded with CAPE at low concentrations, enabling selective cytotoxicity against targeted cancer cells while sparing healthy cells. This approach prevents toxicity associated with high-dose CAPE, allows the drug to cross the blood-brain barrier, and ensures long circulation time. Preclinical studies demonstrated strong selective cytotoxicity against SH-SY5Y cells without adverse effects on normal cells.